Equibles does not estimate personal net worth.
Get an email with a short summary when Zevra Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ZVRA alertsThe proxy statement of Zevra Therapeutics, Inc. reports total compensation of $1,814,465 for Joshua M. Schafer in fiscal 2023, including a base salary of $452,333. Joshua M. Schafer has spoken on 1 earnings call across 1 company, most recently for Zevra Therapeutics, Inc. on November 3, 2026. Zevra Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Zevra Therapeutics, Inc. includes Christal M.M. Mickle (CEO), Neil F. McFarlane (CEO and Board Member), Richard W. Pascoe (CEO) and 7 others.
“We continue to build the foundation for sustained life of growth in patient identification, disease awareness, and stakeholder engagement. Our progress is reflected not only in the 197 prescription enrollment forms submitted since launch, but also in our broader activity and growing awareness across the NPC community.”
Proxy statement
Start not stated–present
Last confirmed April 3, 2024
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Zevra Therapeutics, Inc. (ZVRA) | Chief Commercial Officer and Executive Vice President, Business Development | $452,333 | $1,814,465 |
